gFET designs for biochip multiplexing

Good afternoon,

In this edition of Archer’s Newsletter we highlight the validation of the Company’s advanced graphene field effect transistor (gFET) design by a commercial foundry partner in the Netherlands.

On 31 July 2023, Archer announced that its advanced gFET design had been sent to a commercial foundry partner in the Netherlands for a whole four-inch wafer run for validation.

The new advanced gFET device designs were fabricated and the whole wafer run foundry process was successful. The manufactured gFET chips create the potential for an early biochip platform technology that would be able to sense different liquid samples to test for multiple diseases at once.

Archer’s biochip graphene sensor technology essentially underwent translation from design to scalable semiconductor processing in a commercial foundry, which is both a key technology development and commercial milestone.

Archer is continuing to strengthen its relationships with global foundry partners to deliver these chips using a streamlined ‘fabless’ commercialisation model, which is further outlined in the Company’s most recent Investor Presentation.

After some time overseas to attend to urgent family matters, I am very pleased to be back in Australia. Archer will be rescheduling the previously postponed webinar, which I will be hosting. Registration details will be provided shortly.

Archer also has its Annual General Meeting planned for late November in Sydney. The Company will reach out to shareholders in advance of this, and I look forwarding to seeing you at the AGM.

Sincerely,

Dr Mohammad Choucair, FRACI FRSN GAICD
Chief Executive Officer
Archer Materials Limited (ASX: AXE)

Click here to view the full Newsletter